Clinical impact of novel treatment strategies
- 4 October 2002
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 21 (45) , 6970-6981
- https://doi.org/10.1038/sj.onc.1205565
Abstract
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. Oncogene also publishes 8 Reviews issues a year, on a broad range of topics.Keywords
This publication has 73 references indexed in Scilit:
- A randomised phase II study of gemcitabine/cisplatin alone and with herceptin in patients with HER2-positive non-small cell lung cancer (nsclc)European Journal Of Cancer, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)Lung Cancer, 2000
- ZD1839 (???Iressa???)*,??? as an Anticancer AgentDrugs, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinicSeminars in Cancer Biology, 1996
- In situ delivery of suicide genes for cancer treatmentEuropean Journal Of Cancer, 1994
- Antisense oligodeoxynucleotidesCurrent Opinion in Oncology, 1994
- GROWTH FACTOR RECEPTOR TYROSINE KINASESAnnual Review of Biochemistry, 1988
- RECEPTORS FOR EPIDERMAL GROWTH FACTOR AND OTHER POLYPEPTIDE MITOGENSAnnual Review of Biochemistry, 1987